Molecular Formula | C14H12N2O2 |
Molar Mass | 240.26 |
Density | 1.329±0.06 g/cm3(Predicted) |
Boling Point | 517.3±19.0 °C(Predicted) |
Solubility | DMSO : 250 mg/mL (1040.54 mM; Need ultrasonic) |
pKa | 8.58±0.20(Predicted) |
Storage Condition | -20°C |
In vitro study | KL1333 is a potent modulator of the cellular levels of NAD⁺, a central co-enzyme in the cell’s energy metabolism. Elevated NAD+ levels triggers the activation of SIRT1 and AMPK, and subsequently activates PGC-1α. |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 4.162 ml | 20.811 ml | 41.622 ml |
5 mM | 0.832 ml | 4.162 ml | 8.324 ml |
10 mM | 0.416 ml | 2.081 ml | 4.162 ml |
5 mM | 0.083 ml | 0.416 ml | 0.832 ml |
biological activity | KL1333 is an oral NAD modulator, and NAD(P)H: quinone oxidoreductase 1 (NQO1) reacts as a substrate, leading to increased intracellular NAD levels through NADH oxidation. Elevated NAD levels trigger activation of SIRT1 and AMPK, and subsequent activation of PGC-1α. KL1333 improves energy metabolism and mitochondrial dysfunction in mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) fibroblasts. Protection of KL1333 against cisplatin-induced ototoxicity in mouse cochlear cultures. |
Target | NQO1 |
Animal Model: | db/db mice |
Dosage: | 80 mg/kg |
Administration: | P.o.; daily for 15 weeks |
Result: | Activated AMPK and SIRT1. |